DoD Amyotrophic Lateral Sclerosis Research Program
Therapeutic/Biomarker Pilot Trial Award
Amount of funding: Direct costs budgeted will not exceed $2,000,000.
Purpose: The ALSRP Therapeutic/Biomarker Pilot Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ALS. Clinical trials may be designed to evaluate promising drugs, biologics, or devices with anticipated therapeutic impact that is supported by strong scientific rationale and existing preclinical data. Projects may range from Phase 1 to small-scale Phase 2 trials and should be designed to de-risk and inform the design of more advanced trials, by investigating safety, feasibility, biomarker application, and therapeutic efficacy in relevant patient populations.
Eligibility: Independent investigators - Faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver obtained through their RPM in RMG prior to the pre-application/letter of intent) may be PI. Early career investigators (defined as independent, non-mentored investigators within 5 years of their last training position e.g., postdoctoral fellowship, medical residency, clinical fellowship as of the application submission deadline) are encouraged to apply.
Not eligible: Instructors, Clinical Instructors, Academic staff-research (i.e., research associates), and postdocs are not eligible for this RFP because Stanford does not consider them to be independent positions.
Pre-application/Letter of intent (required) deadline: April 9, 2021 via eBrap
Please include your RPM’s name as business official in the pre-application.
Institutional representative (RPM/RMG or CGO/OSR) deadline: July 8, 2021
Full proposal deadline: July 15, 2021 via grants.gov